[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"glp1-r-related-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:glp1-r-related-disease":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,43,67],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100593415","effect-of-prolonged-fasting-time-on-gastric-residual-volume-in-patients-taking-glp1-receptor-agonists-100593415",false,"NCT07006142","Effect of Prolonged Fasting Time on Gastric Residual Volume in Patients Taking GLP1 Receptor Agonists","Inclusion Criteria:\n\n* Patients undergoing elective upper endoscopy with gastroenterology team\n\nExclusion Criteria:\n\n* Urgent or emergent procedure\n* Inclusion of colonoscopy or antegrade small bowel enteroscopy in planned procedure\n* Upper GI barium study performed in past 24 hours.\n* Gastroparesis\n* Achalasia\n* Pancreatitis\n* Use of outpatient pro-motility medications\n* Patient refusal\n* Inability for patient to provide own consent","ALL","18 Years",{"count":18,"type":19},150,"ESTIMATED","INTERVENTIONAL",[22],"NA","The aim of this study is to determine whether a modified fasting protocol can reduce the potential risk of aspiration for patients currently prescribed GLP1-RAs.",[25,26],"Upper Endoscopy","GLP1-R-related Disease",[28,29],"GLP1 receptor agonists","upper endoscopy","RECRUITING","2026-06-01",{"date":33,"type":34},"2026-06-03","ACTUAL",{"date":36,"type":34},"2025-08-01",{"date":38,"type":19},"2026-08-30",{"name":40,"class":41},"Mayo Clinic","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":15,"minAge":16,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":20,"phases":53,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":42},"100587362","evaluate-the-detection-of-retained-gastric-contents-and-assess-safety-using-the-flower-capsule-endoscopy-in-healthy-individuals-and-glp-1-receptor-agonist-users-100587362","NCT06927401","Evaluate the Detection of Retained Gastric Contents and Assess Safety Using the Flower Capsule Endoscopy in Healthy Individuals and GLP-1 Receptor Agonist Users","Inclusion Criteria:\n\n1. Age \\> 18 years and \\\u003C 65 years (male or female)\n2. Willing and able to sign an IEC-approved informed consent form\n3. Willing and able to comply with all study requirements\n\nExclusion Criteria:\n\n1. History of gastrointestinal disorders\n2. History of gastroparesis\n3. History of prior gastric surgery\n4. Swallowing disorders\n5. Contraindications to EGD or capsule endoscopy\n6. Use of GLP-1 receptor agonists in the last 3 months\n7. Diagnosed with diabetes mellitus\n8. Classified as obese (based on BMI criteria)\n9. Pregnant or lactating",true,"65 Years",{"count":52,"type":19},36,[22],"Clinical Study Overview Feasibility Study Plan (Study 1: Healthy Participants) Study 1- Confirming Flower capsule performance characteristics in detection of retained gastric contents greater than 1.5mL\u002Fkg in Healthy volunteers\n\n1\\. Study Purpose\n\na. A controlled, prospective, between-participants study design to assess Flower in detecting the presence or absence of retained gastric contents (RGC), using sedated esophagogastroduodenoscopy (EGD) as the ground truth for an empty stomach and known ingested volume as the ground truth for a fed participant.\n\n2\\. Study Endpoints\n\na. Primary i. Visualization of Retained Gastric Contents b. Secondary i. Gastric mucosal visualization of the seven anatomical landmarks of the stomach (fundus, cardia, lesser gastric curvature, greater gastric curvature, angulus, antrum, and pylorus) ii. Gastric Cleanliness iii. Adverse events defined as capsule retention, capsule aspiration, perforation, nausea, and pain iv. Maximum, tolerated water consumed v. Patient tolerance vi. Exploratory attempts for successful swallowing vii. Exploratory minimum and maximum water volume for optimal Flower performance viii. Time required for gastric examination completion by Flower",[56,26],"Endoscopy, Digestive System","NOT_YET_RECRUITING","2025-04-14",{"date":60,"type":34},"2025-04-15",{"date":62,"type":19},"2025-04-08",{"date":64,"type":19},"2025-08-30",{"name":66,"class":41},"Asian Institute of Gastroenterology, India",{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":49,"sex":15,"minAge":16,"maxAge":73,"enrollmentInfo":74,"targetDuration":76,"studyType":77,"phases":4,"briefSummary":78,"conditions":79,"keywords":83,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":42},"100571856","glucagon-like-peptide-1-receptor-petct-in-glp-1r-related-disease-100571856","NCT06725693","Glucagon-like Peptide-1 Receptor PET\u002FCT in GLP-1R Related Disease","Inclusion Criteria:\n\n\\- (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled Exendin 4 PET\u002FCT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n\nExclusion Criteria:\n\n\\- (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.","80 Years",{"count":75,"type":19},500,"7 Days","OBSERVATIONAL","To evaluate the potential usefulness of 68Ga\u002F18F-Exendin 4 positron emission tomography\u002Fcomputed tomography (PET\u002FCT) for the diagnosis of primary and metastatic lesions in various GLP-1R-related disease patients.",[26,80,81,82],"Tumor","Insulinoma","Positron Emission Tomography",[84,85],"PET\u002FCT","GLP1-R","2025-02-07",{"date":88,"type":34},"2025-02-11",{"date":90,"type":34},"2019-02-01",{"date":92,"type":19},"2027-11-01",{"name":94,"class":41},"Tianjin Medical University"]